SG11202008177WA - Compstatin analogues and their medical uses - Google Patents

Compstatin analogues and their medical uses

Info

Publication number
SG11202008177WA
SG11202008177WA SG11202008177WA SG11202008177WA SG11202008177WA SG 11202008177W A SG11202008177W A SG 11202008177WA SG 11202008177W A SG11202008177W A SG 11202008177WA SG 11202008177W A SG11202008177W A SG 11202008177WA SG 11202008177W A SG11202008177W A SG 11202008177WA
Authority
SG
Singapore
Prior art keywords
medical uses
compstatin analogues
compstatin
analogues
medical
Prior art date
Application number
SG11202008177WA
Other languages
English (en)
Inventor
Pernille Tofteng Shelton
Jacob Ulrik Fog
Jens Kvist Madsen
Original Assignee
Zp Spv 3 K/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zp Spv 3 K/S filed Critical Zp Spv 3 K/S
Publication of SG11202008177WA publication Critical patent/SG11202008177WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
SG11202008177WA 2018-02-27 2019-02-26 Compstatin analogues and their medical uses SG11202008177WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18158834 2018-02-27
EP18214949 2018-12-20
PCT/EP2019/054685 WO2019166411A1 (en) 2018-02-27 2019-02-26 Compstatin analogues and their medical uses

Publications (1)

Publication Number Publication Date
SG11202008177WA true SG11202008177WA (en) 2020-09-29

Family

ID=65516661

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008177WA SG11202008177WA (en) 2018-02-27 2019-02-26 Compstatin analogues and their medical uses

Country Status (17)

Country Link
US (1) US11965039B2 (ru)
EP (1) EP3759120A1 (ru)
JP (1) JP2021515759A (ru)
KR (1) KR20200135797A (ru)
CN (1) CN112041330A (ru)
AU (1) AU2019228639A1 (ru)
BR (1) BR112020017385A2 (ru)
CA (1) CA3091993A1 (ru)
CL (1) CL2020002197A1 (ru)
CO (1) CO2020011027A2 (ru)
IL (1) IL276877A (ru)
MX (1) MX2020008902A (ru)
PE (1) PE20201254A1 (ru)
RU (1) RU2020128624A (ru)
SG (1) SG11202008177WA (ru)
TW (1) TW202000686A (ru)
WO (1) WO2019166411A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019247467B2 (en) 2018-04-06 2023-01-19 The Trustees Of The University Of Pennsylvania Compstatin analogs with increased solubility and improved pharmacokinetic properties
KR20220066287A (ko) * 2019-08-27 2022-05-24 제트피 에스피브이 3 케이/에스 콤프스타틴 유사체 및 이의 의약 용도
AU2021309548A1 (en) * 2020-07-16 2023-02-23 Zp Spv 3 K/S Inhibitors of complement factor C3 and their medical uses
MX2023008330A (es) 2021-01-20 2024-01-18 Viking Therapeutics Inc Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505068A (ja) 1996-03-13 2000-04-25 トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 補体活性化を阻害する新規ペプチド類
DE69737479T4 (de) 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
DE69732640T2 (de) 1996-09-09 2006-01-12 Zealand Pharma A/S Festphasen-peptidsynthese
AU4648197A (en) 1997-09-17 1999-04-05 Burnham Institute, The Peptides and peptidomimetics for inhibiting complement activation
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
EP1956000B1 (en) 1999-03-17 2016-10-05 Novo Nordisk A/S Acylating agents useful for acylating peptides
AU2003275075A1 (en) 2002-09-20 2004-04-08 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved activity
CN105582523B (zh) 2005-10-08 2022-04-15 阿佩利斯制药公司 用于眼部病症的补体抑制素和其类似物
CA2971349C (en) 2005-11-28 2020-09-08 The Trustees Of The University Of Pennsylvania Potent compstatin analogs
US8442776B2 (en) 2007-06-08 2013-05-14 The Trustees Of The University Of Pennsylvania Structure of compstatin-C3 complex and use for rational drug design
US8946145B2 (en) * 2009-05-01 2015-02-03 The Trustees Of The University Of Pennsylvania Modified compstatin with peptide backbone and C-terminal modifications
CA2813049A1 (en) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
DK2753636T3 (da) * 2011-09-07 2020-02-03 Univ Pennsylvania Compstatinanaloger med forbedret farmakokinetiske egenskaber
US20160194359A1 (en) 2012-11-15 2016-07-07 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
WO2014100407A1 (en) 2012-12-19 2014-06-26 The Regents Of The University Of California Compstatin analogs
KR20220066287A (ko) * 2019-08-27 2022-05-24 제트피 에스피브이 3 케이/에스 콤프스타틴 유사체 및 이의 의약 용도

Also Published As

Publication number Publication date
AU2019228639A1 (en) 2020-09-17
WO2019166411A1 (en) 2019-09-06
CA3091993A1 (en) 2019-09-06
RU2020128624A (ru) 2022-03-28
EP3759120A1 (en) 2021-01-06
BR112020017385A2 (pt) 2020-12-15
US20230192770A1 (en) 2023-06-22
IL276877A (en) 2020-10-29
MX2020008902A (es) 2020-12-03
KR20200135797A (ko) 2020-12-03
US11965039B2 (en) 2024-04-23
TW202000686A (zh) 2020-01-01
CN112041330A (zh) 2020-12-04
CL2020002197A1 (es) 2021-03-05
CO2020011027A2 (es) 2020-12-10
PE20201254A1 (es) 2020-11-16
JP2021515759A (ja) 2021-06-24

Similar Documents

Publication Publication Date Title
IL284835A (en) Pharmaceutical combination containing TNO155 and ribociclib
IL276877A (en) Compstatin analogs and their medical uses
IL253872A0 (en) Unnatural semaphorins 3 and their medicinal use
IL290858A (en) Compstatin analogs and their medical uses
ZA201907833B (en) Heteroarylphenylaminoquinolines and analogues
GB201711749D0 (en) Cyclosporin analogues and uses thereof
HK1255425A1 (zh) 粘貼部件以及醫療器械
SG11202006669RA (en) Peptides and uses thereof
ZA201801134B (en) Hydroxytriazine compound and medical use thereof
GB201709840D0 (en) Methods and medical uses
EP3735277C0 (en) MEDICAL MATERIALS AND DEVICES
EP3578566C0 (en) BIOCIDAL PEPTIDE AND MEDICINAL PREPARATION ON THIS BASIS
ZA201904386B (en) S-arrestin peptides and therapeutic uses thereof
GB201714409D0 (en) Oligonucleotides and analogues thereof
GB2600270B (en) Polymer-comrprising medical devices and uses thereof
EP4069233A4 (en) PHARMACEUTICAL COMBINATION AND USE THEREOF
GB2582571B (en) Peptides and use thereof
GB2561945B (en) Tissue stain and use thereof
GB201906914D0 (en) Substituted naphtahlene diimdes and their use
GB201807050D0 (en) Medical uses
GB201714510D0 (en) Prothesis and othosis
GB201708081D0 (en) Surgical assembly and system
GB201802743D0 (en) Medicament and use thereof
IL292646A (en) Pharmaceutical combination and its use
GB201806133D0 (en) Methods and medical uses